GCP
KALA icon

GSA Capital Partners’s KALA BIO KALA Stock Holding History

GSA Capital Partners’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,689
Closed -$15K – 1958
2026
Q1 		$15K Buy
+1,689
New +$35.7K ﹤0.01% 1649
2022
Q3 		– Sell
-5
Closed -$4K – 1700
2022
Q2 		$4K Sell
5
-6
-55% -$9.41K ﹤0.01% 1336
2022
Q1 		$38K Buy
+11
New +$28.8K 0.01% 1346
2021
Q4 		– Sell
-10
Closed -$66K – 1601
2021
Q3 		$66K Buy
+10
New +$86.3K 0.01% 1342
2021
Q2 		– Sell
-9
Closed -$156K – 1459
2021
Q1 		$156K Buy
9
+5
+125% +$97.6K 0.03% 950
2020
Q4 		$71K Buy
+4
New +$75.3K 0.01% 1124

Other funds holding KALA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

GSA Capital Partners's KALA Position: Q2 2026 in Review

GSA Capital Partners sold out of KALA BIO (KALA) in Q2 2026, closing a stake of 1,689 shares — an estimated $15K sold.

GSA Capital Partners first reported a position in KALA in Q4 2020 and held it in 6 quarters. The position peaked at $156K in Q1 2021. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.

  • GSA Capital Partners reported no remaining KALA BIO position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 1,689 KALA BIO shares in Q2 2026, an estimated $15K.
  • GSA Capital Partners first reported a position in KALA BIO in Q4 2020 and held it in 6 quarters.
  • GSA Capital Partners's KALA BIO position peaked at $156K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.